|
Age, years
|
58 ± 9
|
53 ± 11
|
0.000
|
|
Female sex, n (%)
|
148 (70)
|
120 (79)
|
0.052
|
|
Body mass index, kg/m2
|
28 ± 5
|
28 ± 5
|
0.78
|
|
Waist circumference, cm
|
92 ± 14
|
96 ± 13
|
0.015
|
|
Cardiovascular risk factors, n (%)
|
|
Smoking
|
42 (20)
|
26 (17)
|
0.51
|
|
Hypertension
|
58 (27)
|
45 (30)
|
0.65
|
|
Dyslipidemia
|
33 (15)
|
54 (36)
|
0.000
|
|
Diabetes
|
0 (0)
|
0 (0)
|
–
|
|
Medication
|
|
Statins
|
14 (6)
|
43 (28)
|
0.000
|
|
Antihypertensive treatment
|
35 (16)
|
45 (30)
|
0.003
|
|
Analytical data
|
|
CRP, mg/dl
|
1.0 (1.0–3.0)
|
3.2 (1.5–5.8)
|
0.000
|
|
ESR, mm/h
|
10 ± 8
|
34 ± 22
|
0.000
|
|
Triglycerides, mg/dl
|
104 ± 50
|
144 ± 92
|
0.000
|
|
HDL cholesterol, mg/dl
|
63 ± 18
|
56 ± 15
|
0.000
|
|
LDL cholesterol, mg/dl
|
135 ± 34
|
121 ± 31
|
0.000
|
|
Total cholesterol, mg/dl
|
219 ± 37
|
206 ± 36
|
0.001
|
|
Lipoprotein A, mg/dl
|
16 (9–39)
|
35 (11–121)
|
0.000
|
|
Apolipoprotein A1, mg/dl
|
191 ± 35
|
170 ± 28
|
0.000
|
|
Apolipoprotein B, mg/dl
|
102 ± 24
|
110 ± 63
|
0.11
|
|
ApoB/ApoA ratio
|
0.55 ± 0.16
|
0.66 ± 0.30
|
0.000
|
|
Atherogenic index
|
3.7 ± 4.0
|
4.0 ± 3.6
|
0.10
|
|
Disease-related data
|
|
Disease duration, years
| |
6.6 (3.3–13.9)
| |
|
ACPA, n (%)
| |
89 (59)
| |
|
Rheumatoid factor, n (%)
| |
109 (72)
| |
|
Erosions, n (%)
| |
55 (36)
| |
|
Extra-articular manifestations, n (%)
| |
16 (11)
| |
|
DAS28-ESR
| |
3.7 ± 1.2
| |
|
DAS28-CRP
| |
2.9 ± 1.0
| |
|
SDAI
| |
15 (8–21)
| |
|
CDAI
| |
9 (5–16)
| |
|
HAQ
| |
0.630 (0.380–1.130)
| |
|
Current prednisone, n (%)
| |
57 (38)
| |
|
Prednisone current doses, mg/day
| |
5 (5–6)
| |
|
NSAIDs, n (%)
| |
69 (46)
| |
|
DMARDs, n (%)
| |
129 (85)
| |
|
Methotrexate, n (%)
| |
113 (75)
| |
|
Biologic drugs, n (%)
| |
35 (23)
| |
|
Anti-TNF-α drugs, n (%)
| |
20 (13)
| |
